Results 151 to 160 of about 7,025 (177)

Novel Peptidylarginine Deiminase Type 4 (PAD4) Inhibitors

ACS Medicinal Chemistry Letters, 2022
Provided herein are novel compounds as peptidylarginine deiminase type 4 (PAD4) inhibitors, pharmaceutical compositions, use of such compounds in treating diseases, and processes for preparing such compounds.
openaire   +2 more sources

Coordination of PAD4 and HDAC2 in the regulation of p53-target gene expression [PDF]

Oncogene, 2010
Histone Arg methylation and Lys acetylation have been found to cooperatively regulate the expression of p53-target genes. Peptidylarginine deiminase 4 (PAD4) is an enzyme that citrullinates histone arginine and monomethyl-arginine residues thereby regulating histone Arg methylation.
Gong Chen, Shen Q, Qiu H
exaly   +3 more sources

Facile Fluorescence‐Based Detection of PAD4‐Mediated Citrullination

ChemBioChem, 2013
AbstractThe post‐translational modifications of histone proteins are highly diverse and dynamic processes. It is becoming increasingly evident that modifying histone proteins can have a direct influence on both cellular homeostasis and disease states. Protein arginine deiminase 4 (PAD4) is an enzyme that converts peptidyl‐arginine to citrulline.
Erin, Wildeman, Marcos M, Pires
openaire   +2 more sources

Plant defence against aphids: the PAD4 signalling nexus

Journal of Experimental Botany, 2014
In Arabidopsis thaliana, PHYTOALEXIN DEFICIENT 4 (PAD4) functions as a key player in modulating defence against the phloem sap-feeding aphid Myzus persicae (Sülzer), more commonly known as the green peach aphid (GPA), an important pest of a wide variety of plants. PAD4 controls antibiosis and antixenosis against the GPA.
Louis, Joe, Shah, Jyoti
openaire   +2 more sources

Structure–Activity Relationship of PAD4 Inhibitors and Their Role in Tumor Immunotherapy

Pharmaceutics
Protein arginine deiminase 4 (PAD4) plays an important role in cancer progression by participating in gene regulation, protein modification, and neutrophil extracellular trap (NET) formation. Many reversible and irreversible PAD4 inhibitors have been reported recently.
Yijiang Jia, Yanming Wang, Yuji Wang
exaly   +4 more sources

In silico targeting PAD4 for the treatment of rheumatoid arthritis

Structural Chemistry, 2019
Rheumatoid arthritis (RA) is an autoimmune disorder that causes chronic inflammation with periodic bursts of activity in multiple synovial joints which lead to irreversible damage of cartilage and bone. Although several drugs that reduce inflammation are used for the treatment of RA, they are often associated with side effects.
Mehul N. Soni, Sivakumar Prasanth Kumar, Kaid Johar SR, Himanshu A. Pandya   +3 more
openaire   +1 more source

Expression of peptidylarginine deiminase type 4 (PAD4) in various tumors

Molecular Carcinogenesis, 2005
AbstractPeptidylarginine deiminase type 4 (PAD4/PADI4) posttranslationally converts peptidylarginine to citrulline, in a process known as citrullination. Evidence suggests that PAD4 plays an essential role in pathogenesis of rheumatoid arthritis (RA).
Xiaotian, Chang, Jinxiang, Han
openaire   +2 more sources

PAD4: pathophysiology, current therapeutics and future perspective in rheumatoid arthritis

Expert Opinion on Therapeutic Targets, 2017
Peptidyl arginine deiminase 4 (PAD4) is an enzyme that plays an important role in gene expression, turning out genetic code into functional products in the body. It is involved in a key post translational modification, which involves the conversion of arginine to citrulline.
Sindhu, Koushik, Nivedita, Joshi, Shruthi, Nagaraju, Sameer, Mahmood, Krishna, Mudeenahally, Ramya, Padmavathy, Sooriya Kumar, Jegatheesan, Ramesh, Mullangi, Sriram, Rajagopal   +8 more
exaly   +3 more sources

AB0132 Prevalence of Soluble PAD4 and Anti-PAD4 Antibodies in Autoimmune Diseases- Association to Several Acpas but Not to Shared Epitopes in Patients with Rheumatoid Arthritis

Annals of the Rheumatic Diseases, 2015
Background Anti-citrullinated proteins/peptides antibodies (ACPAs) are major predictor of disease severity of patients with rheumatoid arthritis (RA). Citrullination is the post-translational modification mediated by peptidylarginine deiminases (PADs). PAD4, one of the PAD isozyme, is expressed in granulocytes and monocytes, as well as in the synovial
N. Umeda, I. Matsumoto, Y. Kondo, H. Tsuboi, Y. Kagami, A. Ishigami, N. Maruyama, T. Sumida   +7 more
openaire   +1 more source

Novel Heterocyclic PAD4 Inhibitors for Treating Diseases

ACS Medicinal Chemistry Letters
Provided herein are novel heterocyclic PAD4 inhibitors, pharmaceutical compositions, use of such compounds in treating multiple diseases, and processes for preparing such compounds.
openaire   +2 more sources